Mounjaro Not Working as Expected? Here's What's Actually Going On

Weight loss on tirzepatide is rarely linear — genuine plateaus are a well-documented part of the clinical picture, not evidence the medicine has stopped working.
The dose you're currently on matters: 2.5mg is a tolerability phase; the doses where most people see meaningful progress start from 5mg upward, rising over several months.
Lifestyle factors, including calorie composition, protein intake, sleep quality and activity level, significantly influence how much the medicine can do.
If progress has genuinely stopped after several months at your highest tolerated dose, a structured prescriber review is the right next step, not stopping abruptly.

If Mounjaro is not working the way you expected, you're almost certainly not doing anything wrong. Weight loss on tirzepatide tends to follow a specific biological pattern, and a week or two of no movement on the scales is a normal part of that process rather than a sign of failure. That said, there are real, fixable reasons why some people stall for longer, and a prescriber review can usually identify them. These are prescription-only medicines; a clinician has to assess what's happening before anything changes.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

A step-by-step look at why Mounjaro may seem to have stopped working, and what to check first

Step 1 — Be honest about which phase of treatment you're actually in

The first pen of Mounjaro contains 2.5mg tirzepatide per dose. That starting strength exists so your body adjusts to the medicine gradually, reducing the chance of nausea. Its job is not weight loss. Many people pick up that first pen expecting results within a fortnight, weigh themselves on day ten, and conclude Mounjaro isn't working for them, a situation we cover in detail for anyone who wants to understand why Mounjaro may not seem to be working and what to do about it. It's an understandable assumption, but it's based on the wrong dose.

Titration typically takes three to four months before most people reach doses in the 7.5mg to 10mg range, where clinical trials recorded the larger reductions. In SURMOUNT-1, average weight loss of around 20% was seen at 15mg after 72 weeks, not 72 days. If you're on week six at 5mg and the scales haven't shifted dramatically, you're still early in a year-long clinical journey. The timeline for Mounjaro to work is measured in months, not weeks, and that's not a disclaimer, it's what the trial data actually show.

A prescriber can tell you whether you're at an appropriate dose for the time you've been on treatment, and whether moving up is clinically the right call.

Step 2 (Check what's eating into the medicine's effect

Tirzepatide reduces appetite and slows gastric emptying) two mechanisms that make eating less easier. What it cannot do is override a significant caloric surplus or compensate for patterns that work against weight loss. The most common culprits our prescribers hear about are: liquid calories that aren't counted (soft drinks, juices, alcohol), meals that have quietly expanded now that eating feels more comfortable, and insufficient protein, which matters because Mounjaro-related weight loss includes some lean muscle mass alongside fat.

Sleep is also relevant and often overlooked. Poor or short sleep raises ghrelin and disrupts the hormones that Mounjaro is partly working through. This doesn't mean you need to overhaul your life overnight. It means that if the medicine has reduced your appetite but your weight hasn't moved in six weeks, it's worth looking at what's landing on the plate and whether your sleep pattern has changed.

Activity level plays a role too, though strength training specifically helps protect muscle. The full Mounjaro treatment guide covers the lifestyle factors that complement the medicine, which are part of the licensed indication for a reason.

Step 3, Distinguish a genuine plateau from a stall that needs clinical attention

Even when everything is going well, the rate of weight loss on tirzepatide typically slows as your body reaches a new lower weight and adapts. This is metabolic adaptation, not the medicine failing. A two-to-four week plateau mid-treatment, especially after a dose stabilisation, is expected. A plateau lasting three or more months at a stable dose, with no dietary or activity explanation, is something different.

If you're wondering whether tirzepatide genuinely isn't working for you rather than just working slowly, the markers to look at are: time on treatment, current dose, any changes in side-effect profile (reduced nausea may signal the body adapting), and whether weight has been completely static or simply slower than expected. Completely static weight over several months at a maintained therapeutic dose does warrant a prescriber conversation.

NICE guidance (TA1026) notes that if less than 5% weight loss occurs after six months at the highest tolerated dose, continuing should be reviewed. That's a clinical benchmark, not a finish line. A review at that point might result in a dose change, a lifestyle referral, or a decision about continuing, none of which you should make alone.

Step 4, Have the prescriber conversation before making any changes

The one thing that consistently delays progress is people adjusting things themselves: skipping doses, cutting the dose, or stopping entirely because they've decided the medicine isn't for them. If you're concerned about Mounjaro's effect on your weight loss specifically, a structured review is far more useful than a self-directed change.

Stopping suddenly has its own implications; if you've been wondering about how to come off Mounjaro responsibly, that process is also something a prescriber should guide. The clinical team at nume reviews every repeat prescription individually, which creates a natural checkpoint, but you can contact our aftercare team any time if you're concerned about your progress, without waiting for the next order. Our FAQs page also covers some of the most common progress questions people raise between reviews.

For wider context on how weight-loss treatment works alongside lifestyle changes, the NICE appraisal of tirzepatide (TA1026) and the NHS tirzepatide medicines page both set out the clinical picture plainly.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions